Join Professors Klaus Rabe and Ian Pavord as they discuss the importance of on-treatment clinical remission as a goal in asthma management.

This video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, features Dr. Marjolein de-Bruin Weller discussing the latest real-world data on the effects of advanced systemic treatments on multiple outcomes including disease activity, patient-reported outcomes, biomarkers, and atopic comorbidities in patients with AD.
Join Prof. Sietze Reitsma for an insightful presentation that will delve into identifying and leveraging key characteristics to optimize patient management and treatment outcomes.
Professor Couillard is a respirologist and the Québec Lung Association Chair of Respiratory Research at the Université de Sherbrooke, Canada. He leads a team investigating ways to use biomarkers to predict and prevent asthma attacks and improve asthma management.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.
An infographic to explore the the key roles of CCL17 (TARC) in atopic dermatitis.
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.

Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.
Join Professors Jean-David Bouaziz, Amy Paller, and Alan Irvine for a dynamic presentation on the multifaceted burden of atopic dermatitis, the evolving concept of disease modification, and how targeted systemic therapies may help improve long-term patient outcomes.
Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.

Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.